At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 100 enrolled
Drug / intervention
Debio 1562 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Patients With Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma and Other Forms of Non-Hodgkin's Lymphoma
In Brief
A Phase 2 clinical trial evaluating Debio 1562 and Rituximab for Diffuse Large B-Cell Lymphoma and B-cell Non-Hodgkin's Lymphoma. Completed, enrolled 100 participants across 39 sites in 9 countries.
Detailed Summary
The primary purpose of the study was to determine the safety and tolerability, anti-tumor activity of the proposed Debio 1562 dose regimens in combination with rituximab.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBelgium, Bulgaria, Czechia, Hungary, Italy, Poland, Switzerland, Ukraine, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 2015
Enrollment StartJun 2016
Primary CompletionJan 2021
Study CompletionJun 2021
TodayJul 2026
First PostedOct 1, 2015
Enrollment StartJun 5, 2016
Primary CompletionJan 13, 2021
Study CompletionJun 25, 2021
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 10.8 years ago
Interventions
Debio 1562drug
Administered as IV Infusion.
Rituximabdrug
Administered as IV Infusion.